Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.
At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.
In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.
Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.
The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.
For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.
Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.
Mirum Pharmaceuticals reported a strong start for its product LIVMARLI, generating $3.1 million in net revenue in Q4 2021. Total revenue for 2021 reached $19.1 million. The company anticipates at least $8.0 million in net sales for LIVMARLI in Q1 2022. Major highlights include the sale of a Rare Pediatric Disease Priority Review Voucher for $110 million and a new patent granted for LIVMARLI, providing protection until 2040. The company reported a Q4 net income of $57.5 million, but a net loss for the year of $84 million.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its fourth quarter and year-end 2021 results on March 9, 2022. Following the report, a conference call will be held to discuss the company’s progress and goals for the upcoming year at 4:30 p.m. ET. Investors can join via dial-in or webcast. Mirum focuses on rare diseases, with its approved treatment, LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is advancing its pipeline with clinical trials for conditions affecting pediatric and adult liver diseases.
On February 10, 2022, Mirum Pharmaceuticals granted inducement awards to two new employees, including non-qualified stock options for 14,200 shares and 7,100 restricted stock units (RSUs) under its 2020 Inducement Plan. The stock options have an exercise price of $22.41, the closing price on the grant date, and vest over four years. The RSUs vest over three years. Mirum, a biopharmaceutical company, focuses on treatments for rare diseases, with an approved drug LIVMARLI for cholestatic pruritus and a late-stage pipeline for liver diseases.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The company is scheduled to present on February 16, 2022, at 4:20 p.m. ET. Mirum is focused on developing treatments for rare diseases, including its approved drug LIVMARLI® for Alagille syndrome. The company also has investigational treatments in clinical trials for various liver diseases, demonstrating its commitment to improving patient outcomes in this field.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced an estimated net product revenue of
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported that on January 10, 2022, its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The inducement awards consist of 51,700 stock options at an exercise price of $15.50 per share and 7,150 restricted stock units. The stock options vest over four years, while the RSUs vest over three years. These awards aim to attract talent to support Mirum's mission in treating rare diseases, with a focus on the company's approved medication LIVMARLI™ and ongoing clinical trials for other treatments.
Mirum Pharmaceuticals (MIRM) will present at the virtual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Chris Peetz will share insights on the company’s strategy and updates on LIVMARLI™ (maralixibat), an oral solution approved for treating cholestatic pruritus in Alagille syndrome patients aged one and older. The presentation is scheduled for January 11 at 1:30 p.m. ET. Mirum will also host a fireside chat at the H.C. Wainwright Virtual BIOCONNECT 2022 Conference. Further information can be found on their website.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has been added to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes NASDAQ-listed companies in the biotechnology and pharmaceutical sectors that meet specific eligibility criteria. Mirum is focused on treating rare liver diseases, with its approved drug LIVMARLI™ for cholestatic pruritus in Alagille syndrome patients. The company is also developing investigational treatments and has acquired options for gene therapies targeting PFIC types 2 and 3.
Mirum Pharmaceuticals presented new analyses from clinical studies of LIVMARLI™ at the NASPGHAN Annual Meeting. The studies focused on children with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC2). In the ICONIC study, 74% of patients showed improvement in pruritus, correlating with enhancements in health-related quality of life (HRQoL) measures, including fatigue and sleep disturbances. Additionally, patients with PFIC2 achieving serum bile acid response also noted significant HRQoL improvements. These findings highlight LIVMARLI's potential in treating rare liver diseases.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced the presentation of five posters on LIVMARLI™ (maralixibat) at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting from December 12-18, 2021. Key studies highlight the treatment's impact on health-related quality of life for patients with Alagille syndrome and BSEP deficiency. The abstracts are accessible via the NASPGHAN website, and LIVMARLI is recognized as a breakthrough therapy for certain cholestatic liver diseases.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
What is the focus of Mirum Pharmaceuticals, Inc.?
What is Maralixibat used for?
Where is Mirum Pharmaceuticals headquartered?
What is Livmarli?
When was Mirum Pharmaceuticals founded?
What is Volixibat being developed for?
What are the recent achievements of Mirum Pharmaceuticals?
How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?
How can I get the latest updates on Mirum Pharmaceuticals?
What products are in Mirum Pharmaceuticals' pipeline?
